Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Speakeasy Cannabis Club. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Speakeasy Cannabis Club's
is considered below, and whether this is a fair price.
Price based on past earnings
Speakeasy Cannabis Club's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Speakeasy Cannabis Club has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Food industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Speakeasy Cannabis Club
expected to grow at an
Unable to compare Speakeasy Cannabis Club's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Speakeasy Cannabis Club's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Speakeasy Cannabis Club's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Speakeasy Cannabis Club is high growth as no earnings estimate data is available.
Unable to determine if Speakeasy Cannabis Club is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Speakeasy Cannabis Club's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Speakeasy Cannabis Club
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Speakeasy Cannabis Club's finances.
The net worth of a company is the difference between its assets and liabilities.
Speakeasy Cannabis Club is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Speakeasy Cannabis Club's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Speakeasy Cannabis Club's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 117.3x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Bin Huang, Ph.D., MBA, has been Chief Executive Officer of Speakeasy Cannabis Club Ltd. since June 2019 and serves its Director. Dr. Huang has been a Director of Geyser Brands Inc. since June 25, 2019 and served as its Board Observer since February, 2019 until June 25, 2019. Dr. Huang served Chief Operating Officer Emerald Health Therapeutics Canada Inc. He served as the President of Emerald Health Botanicals at Emerald Health Therapeutics, Inc. Dr. Huang served as the Chief Executive Officer of Emerald Health Therapeutics, Inc. since January 19, 2015 until September 27, 2017 and served as its President and Chief Operating Officer since December 1, 2014 until September 27, 2017. Dr. Huang served as the Chief Executive Officer and President of Wex Pharmaceuticals Inc. since joining November 20, 2007. She served as the Chief Executive Officer and President of Millenium Biologix Corp. since September 1, 1999. She has extensive senior executive management experience. She served as Chief Financial Officer of Wex Pharmaceuticals Inc. from November 20, 2007 to July 1, 2008. She began her career as a Research Scientist with Allelix Crop Technologies focusing on improving canola growth traits such as yield and disease-tolerance. She served as Director of IP & Business Development of Chemokine Therapeutics Corp. since October 2006 and also served as its Vice President of its Business Development from May 2007 to November 16, 2007. Dr. Huang served as the Chief Executive Officer of GeneHarbor Technologies Limited from December 2004 to September 2006. She served as the President and Chief Executive Officer of Cytovax Biotechnologies Inc. from September 1999 to December 2004. Dr. Huang served as Vice President of Business Development of Monsanto Canada and Vice President of Research and Development of Lorus Therapeutics Inc. She served as Equity Analyst of GMP Securities L.P., Research Division. She served as a Biotechnology Analyst and served as a Partner with GMP Securities and has acted as a director of several Canadian biotechnology companies. She served as a Director of Quest PharmaTech, Inc. since November 10, 2014 until November 27, 2015. Dr. Huang served as a Director of Quest PharmaTech Inc. from December 2006 to January 15, 2009. She served as a Director of Millenium Biologix Corp. since September 1,1999. She served as a Director of Afexa Life Sciences Inc. (also known as CV Technologies Inc.) and Cytovax Biotechnologies Inc. She served a Director of Emerald Health Therapeutics, Inc. until April 24, 2015. Dr. Huang received her Ph.D. in Plant Cell Biology from the University of East Anglia in Norwich, UK, Master of Business Administration degree in Finance from the University of Toronto and her BSc in Plant Genetics from Wuhan University, China.
Insufficient data for Bin to compare compensation growth.
Insufficient data for Bin to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure
Average tenure of the
Speakeasy Cannabis Club
management team in years:
The average tenure for the Speakeasy Cannabis Club management team is less than 2 years, this suggests a new team.
Is Speakeasy Cannabis Club (CNSX:EASY) Using Debt In A Risky Way?
CNSX:EASY Historical Debt, July 25th 2019 A Look At Speakeasy Cannabis Club's Liabilities We can see from the most recent balance sheet that Speakeasy Cannabis Club had liabilities of CA$1.33m falling due within a year, and liabilities of CA$100.0k due beyond that. … Succinctly put, Speakeasy Cannabis Club boasts net cash, so it's fair to say it does not have a heavy debt load! … If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.